查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1614051

藥物製劑市場：按劑型、技術、治療領域和最終用戶 - 2025-2030 年全球預測

Drug Formulation Market by Dosage Form, Technology, Therapeutic Area, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 182 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年，藥物製劑市場價值為2.42兆美元，預計2024年將達到2.55兆美元，複合年成長率為5.70%，到2030年將達到3.56兆美元。

藥物製劑的範圍包括將化合物創造成安全有效的藥物供患者使用。它涉及確定藥物的成分、劑型、功效、穩定性和藥物傳輸機制。藥物製劑的需求源自於提高生物有效性度、確保安全性和延長藥物保存期限的需要。應用範圍涵蓋製藥、食品和生物技術產業，最終用途集中於患者治療需求、動物用藥品和臨床試驗。關鍵的成長要素包括慢性病的增加、人口老化、技術進步以及製藥公司研發支出的增加。最新的潛在商機在於基因組和蛋白質體學研究驅動的個人化醫療和生技藥品的擴展，以及奈米技術等藥物傳遞系統，可以顯著提高治療的功效和標靶性。為了抓住這些機會，公司需要投資研發合作並採用多功能製造流程。

主要市場統計
基準年[2023] 2.42兆美元
預計年份 [2024] 2.55兆美元
預測年份 [2030] 3.56兆美元
複合年成長率（%） 5.70%

然而，市場面臨著巨大的挑戰，包括複雜的法律規範、高昂的開發成本以及通常與藥物配方相關的冗長的核准流程。此外，來自學名藥和生物製藥的競爭可能會阻礙市場成長。考慮到這些因素，創新應集中於開發具有改進的遞送系統的製劑，例如口服薄膜製劑和經皮貼劑製劑。探索環保製程和永續方法可以提高成本效率並應對不斷提高的環境標準。藥物製劑市場是一個由技術和臨床進步驅動的充滿活力的市場，但由於監管變化和經濟狀況而繼續受到外部壓力。為了保持成長並獲得競爭優勢，公司應尋求策略夥伴關係，將數位技術納入製劑開發，並透過適應性強的藥物輸送解決方案來應對新興市場。

市場動態：揭示快速發展的藥物製劑市場的關鍵市場洞察

供需的動態交互作用正在改變藥品製劑市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時也能幫助消費行為及其對製造業的影響。

  • 市場促進因素
    • 慢性病流行及有效治療的必要性
    • 政府鼓勵藥物開發和發現的舉措
    • 個人化醫療和客製化醫療的興起
  • 市場限制因素
    • 藥品和藥品召回問題
  • 市場機會
    • 藥物傳輸和給藥技術的進步
    • 學名藥開發CDMO投資
  • 市場挑戰
    • 複雜配方的開發與加工

波特五力：駕馭藥物製劑市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解藥品製劑市場的外部影響

外部宏觀環境因素在塑造藥物製劑市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解藥品製劑市場的競爭狀況

對藥物製劑市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣藥物製劑市場供應商績效評估

FPNV定位矩陣是評估藥品製劑市場供應商的重要工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製藥物製劑市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，藥物製劑市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點關注可望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 慢性病的流行和有效治療的需要
      • 政府鼓勵藥物開發和發現的努力
      • 個人化醫療和治療方法的興起
    • 抑制因素
      • 因不利事件而召回
    • 機會
      • 藥物傳輸和給藥技術的進步
      • 學名藥開發CDMO投資
    • 任務
      • 藥物配方的複雜開發與加工
  • 市場區隔分析
    • 劑型：口服製劑在慢性治療的便利性與有效性
    • 最終用戶：藥廠加大藥物研發投資
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章以劑型分類的藥物製劑市場

  • 吸入製劑
    • 乾粉吸入器
    • 噴霧器
    • 加壓定量吸入器
  • 口服製劑
    • 膠囊
    • 軟糖
    • 錠劑和錠劑
    • 粉末/顆粒
    • 藥片
  • 腸外製劑
    • 乳液
    • 凝膠
    • 粉末
    • 解決方案
    • 暫停
  • 局部製劑
    • 霜、乳液、泡沫
    • 凝膠劑、酊劑、粉末
    • 軟膏和油
    • 貼上
    • 噴霧和補丁

第7章藥物製劑市場：依技術分類

  • 速效製劑
  • 脂質體製劑
  • 微球製劑
  • 改良釋放製劑
  • 奈米配方
  • 自乳化給藥系統
  • 固體分散體製劑

第8章依治療領域分類的藥物製劑市場

  • 心血管
  • 中樞神經系統
  • 皮膚科
  • 內分泌學
  • 胃腸道
  • 免疫學
  • 感染疾病
  • 腫瘤學
  • 眼科
  • 疼痛管理
  • 呼吸系統

第9章藥物製劑市場：依最終使用者分類

  • 學術/研究機構
  • 合約開發和製造組織
  • 醫院/診所
  • 製藥公司

第10章美洲藥物製劑市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太藥物製劑市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲藥品製劑市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • Glenmark 在印度推出針對 2 型糖尿病患者的三重藥物配方
    • Neurocline Biosciences 宣布美國FDA 已接受其 INGREZZA（Valbenazine）口服顆粒噴劑新藥申請
    • 默克和 XtalPi 合作利用人工智慧技術最佳化藥物處方
  • 戰略分析和建議

公司名單

  • 3M Company
  • AbbVie Inc.
  • Amgen, Inc.
  • AstraZeneca plc.
  • Bayer AG
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Catalent, Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Gerresheimer AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc
  • Glenmark Pharmaceuticals Limited
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Marksans Pharma Ltd.
  • Medicef Pharma
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Teva Pharmaceuticals Industries Ltd.
  • The Bristol-Myers Squibb Company
Product Code: MRR-351BAD50373D

The Drug Formulation Market was valued at USD 2.42 trillion in 2023, expected to reach USD 2.55 trillion in 2024, and is projected to grow at a CAGR of 5.70%, to USD 3.56 trillion by 2030.

The scope of drug formulation encompasses the creation of chemical compounds into safe and effective drugs for patient use. It involves determining the drug's composition, dosage form, efficacy, stability, and delivery mechanism. The necessity for drug formulation arises from the requirement to enhance bioavailability, ensure safety, and extend the drug's shelf life. Applications are widespread across pharmaceuticals, nutritional supplements, and biotechnology industries, with end-use focused on patient therapeutic needs, veterinary medicine, and clinical trials. Key growth factors include rising chronic diseases, an aging population, technological advancements, and increased R&D expenditure by pharmaceutical companies. The latest potential opportunities lie in personalized medicine and biologics, driven by genomics and proteomics research, and the expansion of drug delivery systems such as nanotechnology, which can significantly improve the efficacy and targeting of therapeutic agents. To seize these opportunities, companies must invest in R&D collaborations and adopt versatile manufacturing processes.

KEY MARKET STATISTICS
Base Year [2023] USD 2.42 trillion
Estimated Year [2024] USD 2.55 trillion
Forecast Year [2030] USD 3.56 trillion
CAGR (%) 5.70%

However, the market faces formidable challenges, such as complex regulatory frameworks, high development costs, and the lengthy approval processes often associated with drug formulation. Furthermore, competition from generic drugs and biopharmaceuticals can hinder market growth. In light of these factors, innovation should focus on developing formulations with improved delivery systems, such as oral thin films and transdermal patches. Research in eco-friendly processes and sustainable practices could lead to cost efficiency and meet rising environmental standards. The drug formulation market is dynamic, driven by technological and clinical advancements, but remains subject to external pressures from regulatory changes and economic conditions. To maintain growth and gain competitive edge, companies should pursue strategic partnerships, embrace digital technologies for formulation development, and cater to emerging markets with adaptive drug delivery solutions.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Drug Formulation Market

The Drug Formulation Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Prevalence of chronic diseases and need for effective treatments
    • Government initiatives encouraging drug development and discovery
    • Rise of personalized and tailored medicine and therapies
  • Market Restraints
    • Adverse recalls of drugs and medications
  • Market Opportunities
    • Advancements in drug delivery and dosage technologies
    • Investments in CDMOs to develop generic drugs
  • Market Challenges
    • Complex development and processing of drug formulations

Porter's Five Forces: A Strategic Tool for Navigating the Drug Formulation Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Drug Formulation Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Drug Formulation Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Drug Formulation Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Drug Formulation Market

A detailed market share analysis in the Drug Formulation Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Drug Formulation Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Drug Formulation Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Drug Formulation Market

A strategic analysis of the Drug Formulation Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Drug Formulation Market, highlighting leading vendors and their innovative profiles. These include 3M Company, AbbVie Inc., Amgen, Inc., AstraZeneca plc., Bayer AG, Boehringer Ingelheim International GmbH, Boston Scientific Corporation, Catalent, Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, Gerresheimer AG, Gilead Sciences, Inc., GlaxoSmithKline plc, Glenmark Pharmaceuticals Limited, Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc., Marksans Pharma Ltd., Medicef Pharma, Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi SA, Teva Pharmaceuticals Industries Ltd., and The Bristol-Myers Squibb Company.

Market Segmentation & Coverage

This research report categorizes the Drug Formulation Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Dosage Form, market is studied across Inhalation Formulations, Oral Formulations, Parenteral Formulations, and Topical Formulations. The Inhalation Formulations is further studied across Dry Powder Inhaler, Nebulizer, and Pressurized Metered Dose Inhaler. The Oral Formulations is further studied across Capsules, Gummies, Lozenges & Pastilles, Powders & Granules, and Tablets. The Parenteral Formulations is further studied across Emulsions, Gels, Powders, Solutions, and Suspensions. The Topical Formulations is further studied across Creams, Lotions, & Foams, Gels, Tinctures, & Powders, Ointments & Oils, Pastes, and Sprays & Patches.
  • Based on Technology, market is studied across Immediate-Release Formulations, Liposomal Formulations, Microsphere Formulations, Modified-Release Formulations, Nanoformulations, Self-Emulsifying Drug Delivery Systems, and Solid Dispersion Formulations.
  • Based on Therapeutic Area, market is studied across Cardiovascular, Central Nervous System, Dermatology, Endocrinology, Gastrointestinal, Immunology, Infectious Diseases, Oncology, Ophthalmology, Pain Management, and Respiratory.
  • Based on End User, market is studied across Academic & Research Institutions, Contract Development & Manufacturing Organizations, Hospitals & Clinics, and Pharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for effective treatments
      • 5.1.1.2. Government initiatives encouraging drug development and discovery
      • 5.1.1.3. Rise of personalized and tailored medicine and therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Adverse recalls of drugs and medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in drug delivery and dosage technologies
      • 5.1.3.2. Investments in CDMOs to develop generic drugs
    • 5.1.4. Challenges
      • 5.1.4.1. Complex development and processing of drug formulations
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Dosage Form: Convenience and effectiveness of oral formulations for chronic treatments
    • 5.2.2. End User: Rising investments in drug developments by pharmaceutical companies
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Drug Formulation Market, by Dosage Form

  • 6.1. Introduction
  • 6.2. Inhalation Formulations
    • 6.2.1. Dry Powder Inhaler
    • 6.2.2. Nebulizer
    • 6.2.3. Pressurized Metered Dose Inhaler
  • 6.3. Oral Formulations
    • 6.3.1. Capsules
    • 6.3.2. Gummies
    • 6.3.3. Lozenges & Pastilles
    • 6.3.4. Powders & Granules
    • 6.3.5. Tablets
  • 6.4. Parenteral Formulations
    • 6.4.1. Emulsions
    • 6.4.2. Gels
    • 6.4.3. Powders
    • 6.4.4. Solutions
    • 6.4.5. Suspensions
  • 6.5. Topical Formulations
    • 6.5.1. Creams, Lotions, & Foams
    • 6.5.2. Gels, Tinctures, & Powders
    • 6.5.3. Ointments & Oils
    • 6.5.4. Pastes
    • 6.5.5. Sprays & Patches

7. Drug Formulation Market, by Technology

  • 7.1. Introduction
  • 7.2. Immediate-Release Formulations
  • 7.3. Liposomal Formulations
  • 7.4. Microsphere Formulations
  • 7.5. Modified-Release Formulations
  • 7.6. Nanoformulations
  • 7.7. Self-Emulsifying Drug Delivery Systems
  • 7.8. Solid Dispersion Formulations

8. Drug Formulation Market, by Therapeutic Area

  • 8.1. Introduction
  • 8.2. Cardiovascular
  • 8.3. Central Nervous System
  • 8.4. Dermatology
  • 8.5. Endocrinology
  • 8.6. Gastrointestinal
  • 8.7. Immunology
  • 8.8. Infectious Diseases
  • 8.9. Oncology
  • 8.10. Ophthalmology
  • 8.11. Pain Management
  • 8.12. Respiratory

9. Drug Formulation Market, by End User

  • 9.1. Introduction
  • 9.2. Academic & Research Institutions
  • 9.3. Contract Development & Manufacturing Organizations
  • 9.4. Hospitals & Clinics
  • 9.5. Pharmaceutical Companies

10. Americas Drug Formulation Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Drug Formulation Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Drug Formulation Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Glenmark Launches Triple Drug Formulation for Type 2 Diabetes Patients in India
    • 13.3.2. Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Application for INGREZZA (valbenazine) Oral Granules Sprinkle Formulation
    • 13.3.3. Merck & XtalPi Collaboration Optimizes Drug Formulations with AI-Powered Techniques
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. 3M Company
  • 2. AbbVie Inc.
  • 3. Amgen, Inc.
  • 4. AstraZeneca plc.
  • 5. Bayer AG
  • 6. Boehringer Ingelheim International GmbH
  • 7. Boston Scientific Corporation
  • 8. Catalent, Inc.
  • 9. Eli Lilly and Company
  • 10. F. Hoffmann-La Roche AG
  • 11. Gerresheimer AG
  • 12. Gilead Sciences, Inc.
  • 13. GlaxoSmithKline plc
  • 14. Glenmark Pharmaceuticals Limited
  • 15. Halozyme Therapeutics, Inc.
  • 16. Johnson & Johnson Services, Inc.
  • 17. Marksans Pharma Ltd.
  • 18. Medicef Pharma
  • 19. Merck & Co., Inc.
  • 20. Novartis AG
  • 21. Pfizer Inc.
  • 22. Sanofi SA
  • 23. Teva Pharmaceuticals Industries Ltd.
  • 24. The Bristol-Myers Squibb Company

LIST OF FIGURES

  • FIGURE 1. DRUG FORMULATION MARKET RESEARCH PROCESS
  • FIGURE 2. DRUG FORMULATION MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. DRUG FORMULATION MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. DRUG FORMULATION MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DRUG FORMULATION MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DRUG FORMULATION MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL DRUG FORMULATION MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. DRUG FORMULATION MARKET DYNAMICS
  • TABLE 7. GLOBAL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRUG FORMULATION MARKET SIZE, BY DRY POWDER INHALER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL DRUG FORMULATION MARKET SIZE, BY NEBULIZER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRUG FORMULATION MARKET SIZE, BY PRESSURIZED METERED DOSE INHALER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL DRUG FORMULATION MARKET SIZE, BY CAPSULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRUG FORMULATION MARKET SIZE, BY GUMMIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL DRUG FORMULATION MARKET SIZE, BY LOZENGES & PASTILLES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS & GRANULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL DRUG FORMULATION MARKET SIZE, BY TABLETS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL DRUG FORMULATION MARKET SIZE, BY EMULSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL DRUG FORMULATION MARKET SIZE, BY POWDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL DRUG FORMULATION MARKET SIZE, BY SUSPENSIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL DRUG FORMULATION MARKET SIZE, BY CREAMS, LOTIONS, & FOAMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL DRUG FORMULATION MARKET SIZE, BY GELS, TINCTURES, & POWDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL DRUG FORMULATION MARKET SIZE, BY OINTMENTS & OILS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL DRUG FORMULATION MARKET SIZE, BY PASTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL DRUG FORMULATION MARKET SIZE, BY SPRAYS & PATCHES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMEDIATE-RELEASE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL DRUG FORMULATION MARKET SIZE, BY LIPOSOMAL FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL DRUG FORMULATION MARKET SIZE, BY MICROSPHERE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL DRUG FORMULATION MARKET SIZE, BY MODIFIED-RELEASE FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL DRUG FORMULATION MARKET SIZE, BY NANOFORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL DRUG FORMULATION MARKET SIZE, BY SELF-EMULSIFYING DRUG DELIVERY SYSTEMS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL DRUG FORMULATION MARKET SIZE, BY SOLID DISPERSION FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL DRUG FORMULATION MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL DRUG FORMULATION MARKET SIZE, BY CENTRAL NERVOUS SYSTEM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL DRUG FORMULATION MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL DRUG FORMULATION MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL DRUG FORMULATION MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL DRUG FORMULATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL DRUG FORMULATION MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL DRUG FORMULATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL DRUG FORMULATION MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL DRUG FORMULATION MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL DRUG FORMULATION MARKET SIZE, BY RESPIRATORY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL DRUG FORMULATION MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL DRUG FORMULATION MARKET SIZE, BY CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. GLOBAL DRUG FORMULATION MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 58. GLOBAL DRUG FORMULATION MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 68. ARGENTINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 69. ARGENTINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 76. BRAZIL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 77. BRAZIL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 78. BRAZIL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 79. BRAZIL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 80. BRAZIL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 81. BRAZIL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 84. CANADA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 85. CANADA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 86. CANADA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 87. CANADA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 88. CANADA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 89. CANADA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. CANADA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 91. CANADA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. MEXICO DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 93. MEXICO DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 94. MEXICO DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 95. MEXICO DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 96. MEXICO DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 97. MEXICO DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 98. MEXICO DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 99. MEXICO DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED STATES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED STATES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED STATES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 103. UNITED STATES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 104. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 105. UNITED STATES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 106. UNITED STATES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 107. UNITED STATES DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED STATES DRUG FORMULATION MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 118. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 119. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 120. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 121. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 122. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 123. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 124. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 125. AUSTRALIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 126. CHINA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 127. CHINA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 128. CHINA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 129. CHINA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 130. CHINA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 131. CHINA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 132. CHINA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 133. CHINA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 134. INDIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 135. INDIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 136. INDIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 137. INDIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 138. INDIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 139. INDIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 140. INDIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 141. INDIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 142. INDONESIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 143. INDONESIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 144. INDONESIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 145. INDONESIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 146. INDONESIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 147. INDONESIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 148. INDONESIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 149. INDONESIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 150. JAPAN DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 151. JAPAN DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 152. JAPAN DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 153. JAPAN DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 154. JAPAN DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 155. JAPAN DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. JAPAN DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 157. JAPAN DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. MALAYSIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 159. MALAYSIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 160. MALAYSIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 161. MALAYSIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 162. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 163. MALAYSIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 164. MALAYSIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 165. MALAYSIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 166. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 167. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 168. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 169. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 170. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 171. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 172. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 173. PHILIPPINES DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 174. SINGAPORE DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 175. SINGAPORE DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 176. SINGAPORE DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 177. SINGAPORE DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 178. SINGAPORE DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 179. SINGAPORE DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. SINGAPORE DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 181. SINGAPORE DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 182. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 183. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 184. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 185. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 186. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 187. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 188. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 189. SOUTH KOREA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 190. TAIWAN DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 191. TAIWAN DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 192. TAIWAN DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 193. TAIWAN DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 194. TAIWAN DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 195. TAIWAN DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. TAIWAN DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 197. TAIWAN DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. THAILAND DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 199. THAILAND DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 200. THAILAND DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 201. THAILAND DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 202. THAILAND DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 203. THAILAND DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. THAILAND DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 205. THAILAND DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 206. VIETNAM DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 207. VIETNAM DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 208. VIETNAM DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 209. VIETNAM DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 210. VIETNAM DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 211. VIETNAM DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 212. VIETNAM DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 213. VIETNAM DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA DRUG FORMULATION MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 223. DENMARK DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 224. DENMARK DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 225. DENMARK DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 226. DENMARK DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 227. DENMARK DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 228. DENMARK DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 229. DENMARK DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 230. DENMARK DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 231. EGYPT DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 232. EGYPT DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 233. EGYPT DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 234. EGYPT DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 235. EGYPT DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 236. EGYPT DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 237. EGYPT DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 238. EGYPT DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 239. FINLAND DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 240. FINLAND DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 241. FINLAND DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 242. FINLAND DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 243. FINLAND DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 244. FINLAND DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 245. FINLAND DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 246. FINLAND DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 247. FRANCE DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 248. FRANCE DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 249. FRANCE DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 250. FRANCE DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 251. FRANCE DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 252. FRANCE DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 253. FRANCE DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 254. FRANCE DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 255. GERMANY DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 256. GERMANY DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 257. GERMANY DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 258. GERMANY DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 259. GERMANY DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 260. GERMANY DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 261. GERMANY DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 262. GERMANY DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 263. ISRAEL DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 264. ISRAEL DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 265. ISRAEL DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 266. ISRAEL DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 267. ISRAEL DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 268. ISRAEL DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 269. ISRAEL DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 270. ISRAEL DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 271. ITALY DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 272. ITALY DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 273. ITALY DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 274. ITALY DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 275. ITALY DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 276. ITALY DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 277. ITALY DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 278. ITALY DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 279. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 280. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 281. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 282. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 283. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 284. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 285. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 286. NETHERLANDS DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 287. NIGERIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 288. NIGERIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 289. NIGERIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 290. NIGERIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 291. NIGERIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 292. NIGERIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 293. NIGERIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 294. NIGERIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 295. NORWAY DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 296. NORWAY DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 297. NORWAY DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 298. NORWAY DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 299. NORWAY DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 300. NORWAY DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 301. NORWAY DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 302. NORWAY DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 303. POLAND DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 304. POLAND DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 305. POLAND DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 306. POLAND DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 307. POLAND DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 308. POLAND DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 309. POLAND DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 310. POLAND DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 311. QATAR DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 312. QATAR DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 313. QATAR DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 314. QATAR DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 315. QATAR DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 316. QATAR DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 317. QATAR DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 318. QATAR DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 319. RUSSIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 320. RUSSIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 321. RUSSIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 322. RUSSIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 323. RUSSIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 324. RUSSIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 325. RUSSIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 326. RUSSIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 327. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 328. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 329. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 330. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 331. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 332. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 333. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 334. SAUDI ARABIA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 335. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY DOSAGE FORM, 2018-2030 (USD MILLION)
  • TABLE 336. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY INHALATION FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 337. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY ORAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 338. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY PARENTERAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 339. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY TOPICAL FORMULATIONS, 2018-2030 (USD MILLION)
  • TABLE 340. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 341. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY THERAPEUTIC AREA, 2018-2030 (USD MILLION)
  • TABLE 342. SOUTH AFRICA DRUG FORMULATION MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 343. SPAIN DRU